Silencing of long non-coding RNA H19 downregulates CTCF to protect against atherosclerosis by upregulating PKD1
Yongyao Yang1, Feng Tang1, Fang Wei1
1Department of Cardiology, Guizhou Provincial People's Hospital, Guiyang 550002, P. R. China.
Abstract:
This study aimed to explore the interactions among long non-coding RNA H19, transcriptional factor CCCTC-binding factor (CTCF) and polycystic kidney disease 1 (PKD1), and to investigate its potentially regulatory effect on vulnerable plaque formation and angiogenesis of atherosclerosis. We established an atherosclerosis mouse model in ApoE knockout mice, followed by gain- and loss-of-function approaches. H19 was upregulated in aortic tissues of atherosclerosis mice, but silencing of H19 significantly inhibited atherosclerotic vulnerable plaque formation and intraplaque angiogenesis, accompanied by a downregulated expression of MMP-2, VEGF, and p53 and an upregulated expression of TIMP-1. Moreover, opposite results were found in the aortic tissues of atherosclerosis mice treated with H19 or CTCF overexpression. H19 was capable of recruiting CTCF to suppress PKD1, thus promoting atherosclerotic vulnerable plaque formation and intraplaque angiogenesis in atherosclerosis mice. The present study provides evidence that H19 recruits CTCF to downregulate the expression of PKD1, thereby promoting vulnerable plaque formation and intraplaque angiogenesis in mice with atherosclerosis.
Insights
Long non-coding RNA H19 recruits CTCF to suppress PKD1, promoting atherosclerosis. Silencing H19 inhibits plaque formation and angiogenesis, offering therapeutic potential for atherosclerosis.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- RNA Biology
Background:
- Atherosclerosis involves complex molecular interactions contributing to vulnerable plaque formation and angiogenesis.
- Long non-coding RNAs (lncRNAs) are increasingly recognized as key regulators in cardiovascular diseases.
Purpose of the Study:
- To elucidate the interaction between lncRNA H19, CTCF, and PKD1 in atherosclerosis.
- To investigate the regulatory role of this axis in vulnerable plaque formation and angiogenesis.
Main Methods:
- Atherosclerosis mouse model established using ApoE knockout mice.
- Gain- and loss-of-function approaches employed to manipulate H19 and CTCF expression.
- Analysis of gene expression (MMP-2, VEGF, p53, TIMP-1) and plaque characteristics.
Main Results:
- H19 was upregulated in atherosclerotic mouse aortas.
- H19 silencing reduced plaque formation and angiogenesis, altering MMP-2, VEGF, p53, and TIMP-1 levels.
- H19 recruited CTCF to suppress PKD1, promoting atherosclerosis progression.
Conclusions:
- H19-CTCF interaction downregulates PKD1, driving vulnerable plaque formation and angiogenesis.
- Targeting the H19/CTCF/PKD1 pathway may offer a novel therapeutic strategy for atherosclerosis.
Related Concept Videos
lncRNA - Long Non-coding RNAs
Experimental RNAi


